Research
Hormonal
Novel anti-obesity medications (AOMs), specifically GLP-1 receptor agonists like semaglutide (2.4 mg weekly), achieve >10% body weight loss and lead to MASH resolution and fibrosis regression in patients with fibrotic MASH, offering a viable alternative to lifestyle changes alone.
Semaglutide 2.4 mg weekly is now FDA-approved for fibrotic MASH. It effectively resolves MASH and regresses fibrosis in many patients, offering a powerful tool when lifestyle changes are insufficient.
StrongSupportsHIGH confidence
semaglutide 2.4 mg once weekly in patients with MASH and fibrosis F2/F3, demonstrated significant improvement in both MASH resolution and liver fibrosis regression of >1 stage, leading to FDA conditional approval for the treatment of patients with fibrotic MASH.
Why this rating
Based on Phase III RCTs (ESSENCE) and pooled data from STEP trials.
Source
Management of obesity in advanced chronic liver disease
Cyrielle Caussy et al. · JHEP Reports · 2026
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →